Yes. You can have Crohn's disease and be overweight, and you can have severe Crohn's disease and be overweight. In a case-control study that matched 100 Crohn's outpatients to 100 healthy controls by age, sex and socioeconomic status, 40% of the Crohn's group had a body mass index of 25 or above. The controls came in at 52%, and the difference between the two groups was not statistically significant (Nic Suibhne 2013). A 2026 review of cardiometabolic care in IBD puts obesity prevalence across the IBD population at around 40% (Plush 2026).
So the stereotype is not just unkind, it is out of date. What makes this question painful is not really the statistics, though. It is the second half of it: whether a body that does not look ill means a disease that is not serious, and whether the people treating you will believe you. This guide answers both, and it is honest about where the research contradicts itself, because on this topic it does so repeatedly.
How common is it actually?
Common enough that "you are too heavy to have Crohn's" is not a clinical observation, it is a guess.
The cleanest number comes from that Irish case-control study, because it matched its controls carefully. Forty per cent of the 100 Crohn's outpatients had a BMI of 25 or above, against 52% of matched healthy controls, with a P value of 0.206 (Nic Suibhne 2013). Read that carefully: the Crohn's group was, if anything, slightly less likely to be overweight, and the study could not show the difference was real. What it rules out is the idea that a Crohn's clinic is full of thin people.
A US review of IBD registries at the Dallas Veterans Affairs Medical Center and Parkland Health found 30.3% of Crohn's patients had a BMI of 30 or above (Flores 2015). Worth flagging an oddity in that paper's own abstract: it reports 32.7% of its whole IBD cohort as obese and 67.6% as non-obese, which adds up to 100.3%. That is a rounding or reporting slip rather than anything sinister, but it is the kind of thing worth noticing before you quote a figure.
The hospital coding data tells you less than it looks like it does. A US Nationwide Inpatient Sample analysis of 282,005 IBD hospitalisations from 2016 to 2018 found only 9.4% carried a secondary diagnosis code for obesity (Dahiya 2022). That is far below any clinic-measured prevalence, which tells you that obesity is under-coded in inpatient records rather than that it is rare. It is a reminder to treat administrative datasets as a measure of what got written down.
Where did "Crohn's makes you thin" come from?
From a real clinical picture, measured in the wrong decade and in the wrong age group.
Weight loss genuinely is a presenting feature of Crohn's disease for many people, and it is most visible in children, where growth failure is a recognised consequence of untreated disease. If that is your side of the problem, our guide to how to gain weight with Crohn's disease covers it directly. The Manitoba figures above show it clearly: at diagnosis, a fifth of the children with Crohn's were underweight and none were obese (Chandrakumar 2020). In the paediatric Swiss IBD cohort, 83.2% of 327 children with IBD were normal weight and only 12.8% were overweight or obese (von Graffenried 2022).
That is the picture the textbooks were built on. It is also a snapshot taken at the worst moment, before treatment. The adult figures are what happens over the following decades: steroid courses, a narrowing safe-food list, activity lost to fatigue and joint pain, appetite returning as inflammation is controlled, and, for most of us, the same background weight gain the rest of the population is experiencing.
A thread in r/CrohnsDisease titled "Fat with Crohn's Disease" drew 156 comments, and the dominant story in it was not steady weight gain but violent oscillation: people describing losing 40 or 50 pounds during a severe flare and regaining all of it plus more once they could eat again, keeping clothes in three or four sizes, and a 70 pound swing across a decade (r/CrohnsDisease thread). Several described a lasting fear of losing weight after a flare that nearly killed them. That is lived experience rather than evidence, but it is a coherent physiological story and it is the one the ranking articles skip.
Does being heavier mean my Crohn's is mild?
No. Four reasonable studies have asked a version of this question and produced three different answers, which is the most honest summary available.
| Study | Population | What it found |
|---|---|---|
| Flores 2015 | 581 US IBD patients, retrospective records | Obese patients less likely to receive anti-TNF, have surgery or be hospitalised. Concluded obesity is "a marker of a less severe disease course" |
| Nic Suibhne 2013 | 100 Crohn's outpatients, prospective | Higher BMI associated with lower CDAI and lower white cell count. No association with need for surgery or steroids |
| Greuter 2020 | 325 obese vs 1,725 normal-weight patients, Swiss IBD Cohort | In Crohn's only: higher CDAI (33 vs 20), less likely to be in remission (OR 0.610), higher risk of complicated disease course (HR 1.197) |
| Oomkens 2025 | 1,066 Dutch registry patients starting non-anti-TNF therapies | Obese patients achieved steroid-free clinical remission at week 24 less often (35.3%, OR 0.578) |
Two of those say a higher BMI travels with quieter disease. Two say the opposite. They cannot all be right about the same thing, and the likely explanation is that they are measuring different things. Flores and Nic Suibhne used cross-sectional snapshots, where a higher BMI may simply mark someone who is currently well enough to eat. Greuter followed the Swiss cohort for six years and found the complicated-course signal only over time, and only in Crohn's, not ulcerative colitis. Oomkens looked specifically at a treatment response window.
The paediatric Swiss cohort adds a fifth answer: overweight and obese children with Crohn's showed no higher clinical or biological disease activity than normal-weight children, with one exception, perianal abscesses and surgery for them, which were more frequent (von Graffenried 2022). That paper's abstract is worth reading carefully, because the sentence listing its weight categories attaches them grammatically to the 181 ulcerative colitis patients while the counts (13 underweight, 272 normal, 22 overweight, 20 obese) sum to the full cohort of 327. We could not reconcile that sentence as written, and read it as describing the whole cohort.
What all of this means practically is narrow but useful: nobody, including your gastroenterologist, can grade your Crohn's by looking at you. If someone in a clinic room implies otherwise, the literature does not back them.
Why can't I lose weight with Crohn's?
Because several of the things that keep your disease quiet also push weight up, and the usual advice collides with your bowel.
There is no single mechanism, and honest answers here are stacked contributors rather than one cause.
Your safe foods are almost all refined carbohydrate. This came up again and again in the threads: potato, white bread, white rice, plain pasta, crackers. It is not a failure of willpower, it is what a narrowed or inflamed bowel tolerates. Our guide to what to eat during a Crohn's flare-up goes into why low-residue eating looks like that and why it is meant to be temporary. The problem is that "temporary" often is not. In a study of 161 IBD outpatients, 92% avoided at least one food during active symptoms and 74% carried on avoiding foods even with no symptoms (Yelencich 2022). A safe-food list built in a flare tends to outlive the flare.
The standard advice is actively unsafe for some people with Crohn's. "Eat more fruit and vegetables" is reasonable general guidance and a genuine hazard if you have a stricture. Several people in the threads described being given exactly that advice by clinicians who had not asked about their disease phenotype.
Activity is not freely available. Fatigue and joint pain both restrict it, and both are common in Crohn's independent of how inflamed your bowel is. Crohn's fatigue in remission covers the fatigue side, and joint pain with Crohn's disease covers the joints, including the fact that enteropathic arthritis does not always track your gut. Nic Suibhne's regression found lower physical activity independently associated with higher current BMI in Crohn's (Nic Suibhne 2013). If you want to work out what movement is realistic for you, can you exercise with Crohn's disease is a better starting point than a generic programme.
Weight cycling is its own problem. Repeated cycles of loss during a flare and regain afterwards are what many people in the threads describe. We could not find a study measuring metabolic consequences of flare-driven weight cycling specifically in Crohn's, so we are not going to assert a mechanism for it. It is a plausible gap in the literature rather than a proven driver.
Other conditions often sit alongside. People in the threads named polycystic ovary syndrome, thyroid disease and ADHD as things that turned out to be part of their weight story. Those are real conditions with real weight effects, but the connection to Crohn's is coincidence rather than consequence, and the point is simply that Crohn's does not exempt you from having something else too.
How much of it is the steroids?
A great deal for many people, but nobody can tell you your personal share, and the best evidence on this is not from IBD.
In a survey of 2,446 adults who had been prescribed at least 60 days of glucocorticoids in a US managed-care population, weight gain was the single most commonly reported adverse effect, named by 70%. More than 90% reported at least one side effect, and every effect studied showed a dose-dependent relationship with cumulative steroid exposure. Even at low doses of 7.5 mg prednisone per day or less, longer duration was significantly associated with weight gain (Curtis 2006). That population was mostly people with rheumatic and other conditions rather than IBD, and it was self-reported by the 38% who returned the survey, so read it as strong evidence about steroids in general rather than a Crohn's-specific number.
The practical consequence is that repeated steroid courses are a weight problem as well as a bone and cataract problem, which is one of the reasons IBD teams try to avoid them. That is a reason to ask your team about steroid-sparing strategies, not a reason to skip a course you have been prescribed.
Do biologics cause weight gain?
The studies disagree, and the disagreement itself is informative.
The largest and cleanest dataset says no. A nationwide Danish registry study followed 851 patients with Crohn's disease or ulcerative colitis through infliximab induction and maintenance. Long-term weight gain was not observed in most patients. Patients with a normal or raised BMI at the start gained an average of less than 2 kg during maintenance. Fewer than 3% gained more than 10% of their baseline body weight. The one striking figure is that underweight women with Crohn's gained an average of 7.5 kg, which is the point: the weight gain concentrated in the people who needed it. The authors concluded that weight gain on anti-TNF therapy is unlikely to be an effect of the drug (Winter 2022).
Two smaller studies point the other way and deserve printing rather than dropping. An Australian single-centre cohort of IBD patients on infliximab for over 12 months found two-thirds gained weight, with a mean change of 3.3 kg (Kaazan 2020). A US paediatric series of 69 children on anti-TNF therapy for a median of 29.3 months found a mean BMI standard deviation score rise of 0.50, and 17% met the study's definition of excess weight gain, including three children reclassified from normal weight to obese (Haas 2017).
Those are not irreconcilable. The Danish study was nationwide and much larger, the other two were single centres with selected follow-up, and none of them can separate the drug from the recovery of appetite and absorption that a working drug produces. The most defensible reading is the one Winter's authors offer: the scale moves because the disease quietened, not because of the molecule. But if you gained weight after starting a biologic, you are not imagining it and you are not alone.
You can be overweight and undernourished at the same time
This is the part the stereotype gets most wrong, and it is the practical reason BMI should not be your main number.
In an Australian cohort of 137 IBD patients aged 18 to 50, whole-body DXA scans and grip strength testing found low lean mass in 21% and sarcopenia in 12%. The finding that matters here: a normal BMI was falsely reassuring in 72% of patients with low lean mass and 76% of those with sarcopenia. Grip strength predicted low lean mass far better than BMI did (odds ratio 4.8 versus 0.7), and low lean mass and sarcopenia, but not BMI or fat mass, predicted osteopenia and osteoporosis (Bryant 2015). If BMI misses three quarters of low muscle mass at normal weight, it does not become more informative higher up the scale.
Low muscle mass may also matter for treatment. In 118 Chinese patients with Crohn's disease treated with infliximab, sarcopenia measured on CT was more common in those who lost response within a year (83.7% versus 60.0%). In that cohort a higher BMI was inversely associated with sarcopenia (OR 0.68) (Li 2025). This is a single retrospective centre, and sarcopenia rates of 60% even in the remission group are strikingly high, which suggests their measurement threshold was generous. Take it as a reason to care about muscle rather than a prognostic tool.
The malnutrition risk is not theoretical. Among the IBD outpatients screened for avoidant restrictive food intake disorder, 17% screened positive, and 60.7% of those who screened positive were at risk of malnutrition, against 15.8% of those who did not (Yelencich 2022). Nothing in that screen asks your weight.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
What your weight does to the numbers your team reads
This is the angle nobody writing about this seems to cover, and it is the one most likely to change a conversation with your gastroenterologist.
A higher BMI raises CRP on its own. In the third US National Health and Nutrition Examination Survey, covering 16,616 people, obesity was associated with substantially higher odds of a raised C-reactive protein: an odds ratio of 2.13 in men and 6.21 in women after adjustment, and the association held even among adults aged 17 to 39 with smokers, inflammatory disease, cardiovascular disease and diabetes excluded (Visser 1999). That study measured the general US population, not people with IBD, and it is the mechanism rather than the effect size that transfers.
But the effect does appear in Crohn's. Nic Suibhne's team described what they called a novel association in their cohort: higher BMI went with higher CRP in Crohn's patients, and they explicitly flagged the long-term implications of that for interpreting inflammatory load (Nic Suibhne 2013).
So if you are carrying extra weight, a mildly raised CRP is a weaker signal in you than the same number would be in a thinner person. That cuts both ways: it can produce worry about inflammation that is not there, and it can make a genuine rise harder to spot against a higher baseline. It is a strong argument for knowing your own well-baseline CRP rather than reacting to a single value.
We looked for evidence on whether BMI shifts faecal calprotectin in the same direction and did not find a study testing it, so we are not going to claim calprotectin is unaffected. What we can say is that calprotectin measures something different, a gut-derived protein in stool rather than a systemic acute-phase reactant, and it is the marker guidelines lean on for Crohn's monitoring. Our guide to high calprotectin but no symptoms covers how to read those results and their day-to-day variability.
One more thing your weight does to the numbers: it does nothing at all to the Harvey-Bradshaw Index, which is the score many IBD teams use to grade Crohn's activity. Its five items are well-being, abdominal pain, liquid stool count, abdominal mass and complications, with no weight component (see our walkthrough of what an HBI score means). If your team scores you on the HBI, your weight is not in the arithmetic and does not need to be defended.
Does weight change how well the drugs work?
Possibly, and the IBD-specific picture is weaker than the headline suggests.
The most-quoted paper here is a systematic review of 54 cohorts covering 19,372 patients across IBD, rheumatoid arthritis, spondyloarthropathies, psoriasis and psoriatic arthritis, of whom 23% were obese. It found patients with obesity had 60% higher odds of failing anti-TNF therapy (OR 1.60), with a dose-response pattern and a 6.5% rise in odds of failure per unit of BMI. Crucially, the authors state that these effects were observed across patients with rheumatic diseases but were not observed in patients with IBD (Singh 2018). That review was funded in part by the Crohn's and Colitis Foundation of America, the NIH and the American College of Gastroenterology, and a correction to it was published later the same year (PLOS ONE Staff 2018); we could not read what the correction changed, as the notice carries no detail beyond pointing at the original article.
So the headline number does not belong to Crohn's disease. If you have seen "obesity makes biologics 60% more likely to fail" repeated on a health site, that is the IBD-excluded finding being applied to IBD.
The paediatric evidence is more specific and more mixed. A retrospective study across 22 IBD centres in 14 countries followed 637 children starting anti-TNF therapy, 140 of whom (22%) were overweight or obese. There was no difference in loss of response between groups. The overweight or obese group did have more dose escalations, and by the end of a mean 141 weeks of follow-up their relapse rate was higher: 64% versus 44% (P less than 0.001), with no difference in the first year (Sila 2025). We should flag that this abstract's concluding sentence reads "Relapse in the first year after anti-TNF was introduced, but risk for relapse was increased at the end of follow-up," which contradicts its own results section stating there was no first-year difference. We could not reconcile the conclusion as written and have gone with the results section.
The Dutch registry looked at a different drug set entirely, excluding anti-TNF and covering thiopurines, vedolizumab, ustekinumab, ozanimod, filgotinib and tofacitinib. There, obesity was associated with lower steroid-free clinical remission at week 24 (adjusted OR 0.537) (Oomkens 2025).
None of this is a reason to change a medication. It is a reason to ask your team whether your drug levels have been checked if you are losing response, since therapeutic drug monitoring is how that question gets answered rather than by reasoning from BMI.
Creeping fat is not the same thing as body fat
Worth separating, because the two get blurred and the conclusion people draw from the blur is wrong.
Creeping fat is the expansion of mesenteric fat that wraps around inflamed and fibrotic intestine in Crohn's disease. A 2020 study in Cell found a subset of mucosal gut bacteria that translocated and stayed viable in creeping fat in surgical resections from Crohn's patients, identified Clostridium innocuum as a signature organism, and characterised the tissue as both pro-fibrotic and pro-adipogenic, proposing that the fat forms as a barrier preventing bacteria spreading systemically (Ha 2020). Parts of that work were confirmed in gnotobiotic mice, so the causal chain is partly animal evidence.
That is a local, disease-driven process happening around your bowel. It is not the fat on your hips, and there is no evidence that losing body weight removes it.
The clinical corollary is that whole-body adiposity measures perform poorly as predictors. In 95 patients who had intestinal resection for symptomatic Crohn's disease, visceral fat area measured on preoperative CT did not differ between those with an uneventful postoperative course and those with complications (median 52.0 versus 41.3 cm², P = 0.465), and showed no correlation with disease behaviour. The authors said plainly that this ran against the existing literature (Argeny 2018). That is a negative study and it deserves to be reported as one.
Surgery: what weight does and does not change
Less than the surgical literature's tone implies, and the studies contradict each other here too.
A retrospective review of 391 intestinal surgeries in IBD patients stratified by BMI found no differences in operative time, blood loss, conversion to open surgery, intraoperative complications, or 30-day total complications, wound infection or anastomotic leak. The authors concluded obesity does not worsen postoperative complication rates (Guardado 2016). One detail in that paper does not hold together: it reports a statistically significant increased postoperative bleeding risk in underweight patients (P = 0.029), then gives the rates as 2.9% underweight, zero normal weight, 2.9% overweight and zero obese. Since the overweight rate is identical to the underweight rate, we could not see how that supports an underweight-specific finding, and we would not quote the bleeding result either way.
The paediatric surgical data leans the other way. Using the NSQIP-Pediatric database, 1,258 intestinal resections in children with Crohn's disease were analysed. Obese children had an adjusted odds ratio of 1.9 for 30-day hospital readmission compared with average-BMI children. That is described in the paper as a two-fold increase, but the 95% confidence interval was 1.0 to 3.8, which touches the no-effect line, so the finding is at the edge of significance rather than robust (Egberg 2021). Only 8% of that cohort was obese, which is part of why the interval is so wide.
The inpatient coding data sits in between: IBD hospitalisations with an obesity code had a longer mean length of stay (5.5 versus 4.9 days), higher charges and a higher proportion of complications, but no difference in inpatient mortality (Dahiya 2022). Administrative data cannot tell you whether obesity or its comorbidities drove that, and the obesity-coded group was older with more comorbidities to begin with.
Did being overweight cause my Crohn's?
The two best syntheses of this question reach opposite conclusions, which is a good reason not to carry the blame.
A pooled analysis of five prospective cohorts, covering 601,009 participants and 10,110,018 person-years, confirmed 563 incident cases of Crohn's disease and 1,047 of ulcerative colitis. Obesity at baseline was associated with an increased risk of Crohn's disease (pooled adjusted HR 1.34, 95% CI 1.05 to 1.71) compared with normal BMI, with each 5 kg/m² increment carrying a 16% higher risk, and each 5 kg/m² increment in BMI at age 18 to 20 carrying a 22% higher risk. No association at all was found with ulcerative colitis (Chan 2022). The authors describe this as increased risk of older-onset Crohn's disease, since these were adult cohorts aged 18 to 98.
A meta-analysis of nine prospective cohort studies published the same year reached different conclusions: no significant difference in Crohn's disease incidence across BMI categories, a 21% lower risk of ulcerative colitis incidence in obesity (RR 0.79), and a significant inverse association between obesity and total IBD incidence (RR 0.76) (Milajerdi 2022).
Two things about that second paper need saying. First, its pooled total-IBD estimate of 0.76 sits below both of its own subtype estimates, since UC came in at 0.79 and Crohn's showed no significant association. We could not reconcile that arithmetic from the abstract. Second, the same abstract's final sentence reports a significant inverse association with total IBD incidence and then says no association was found between increasing BMI and IBD incidence, in the same sentence. Third, it applied a fixed-effects model to a pooled estimate with I² of 93.2%, which is very high heterogeneity for that choice.
This is a field that has already had this argument in print: a letter to Obesity Reviews titled "Metaanalysis on obesity and risk of inflammatory bowel disease: reanalysis is needed" was published in 2020, with a reply from the original authors in the same issue (Milajerdi 2020; Rahmani 2020). Neither letter has an abstract we could read, so we cite them only for the fact that the dispute happened, not for what either side argued.
Where does that leave you? With a population-level association of modest size that may exist for Crohn's and probably does not for ulcerative colitis, and that in any case says nothing about causation in one individual. Plenty of thin people develop Crohn's disease and most people with obesity never do.
What to track when weight is not your signal
Track what moves with disease activity, and log weight as context rather than as a verdict.
If your weight does not fall when you are flaring, you have lost the crudest early-warning sign that other people rely on, and you need to replace it with better ones. Here is what is worth capturing:
| What to log | Why it earns its place |
|---|---|
| Stool frequency and consistency | The liquid stool count is a scored HBI item and moves with activity |
| Urgency and any accidents | Often the first thing to change and routinely left out of scores |
| Night-time waking to open your bowels | Waking at night is a recognised red flag, not ordinary variation |
| Abdominal pain, with location | HBI item, and location matters for a stricture question |
| Any blood | Always worth reporting rather than absorbing |
| Faecal calprotectin results with dates | Lets your team see a trend rather than a single value |
| Steroid course start and stop dates | Makes the weight curve interpretable instead of mysterious |
| What you actually ate during bad patches | This is usually where the calories change, and it is data your dietitian can use |
| One function marker, such as flights of stairs or grip | Function tracks muscle, which BMI hides |
| Weight, weekly and at the same time of day | Context for the above, not a measure of inflammation |
The point of writing it down is that you arrive at an appointment with a trend rather than an adjective. If you use a tracker rather than paper, Clairop logs meals, bowel movements and symptoms and turns them into a one-page report you can take to an appointment. If you would rather work out what to ask once you are in the room, questions to ask your doctor about Crohn's disease covers that ground.
A worked example: twelve weeks and one appointment
A composite, built from the sub-questions in the threads rather than from any real person.
Weeks 1 to 4. You are 12 kg heavier than two years ago, after two prednisolone courses and a year on a biologic. Your weight has been flat for four months, but your stools have crept from three to five a day and you have started waking once a night. You log both, plus urgency, and you write down the steroid dates you can remember.
Weeks 5 to 8. You notice the pattern the log makes visible: the night-time waking started three weeks before the stool count moved, and it is not related to what you ate. You request a calprotectin test and it comes back raised compared with the one from last year. Your weight has not moved at all.
Weeks 9 to 12. At the appointment you hand over one page: stool frequency by week, nights woken, urgency, the two calprotectin values with their dates, and a line saying your weight has been stable throughout. You ask two things: whether your drug levels should be checked, and whether a dietitian referral could help widen your safe-food list without triggering symptoms.
What made that appointment work was not the weight. It was the night-time waking and the calprotectin trend, neither of which would have been visible from the scale. For the broader question of separating a flare from something else, how to tell if you're in a Crohn's flare covers the look-alikes.
Weight loss medications and surgery: what the evidence shows
There is now real data in IBD specifically, it is observational, and none of it is a reason to start anything without your IBD team.
On GLP-1 receptor agonists, a systematic review and meta-analysis pooled 11 studies covering 16,242 patients with IBD treated with these drugs. At three months, weight loss was substantial: 9.6 kg with semaglutide, 9.4 kg with liraglutide and 11.8 kg with tirzepatide. In meta-analysis, GLP-1 receptor agonist use was associated with a lower risk of surgery (log hazard ratio 0.61; odds ratio 0.46 by event frequency), and a sensitivity analysis found lower hospitalisation and surgery risk in those with a BMI of 30 or above. The authors state plainly that their findings require confirmation in prospective trials (Bayoumy 2025). Observational data on a drug prescribed to people healthy enough to be prescribed it carries an obvious selection problem, so treat the surgery finding as promising rather than settled.
On bariatric surgery, a Swedish nationwide cohort matched 399 patients with IBD and obesity who had bariatric surgery to 399 who did not, using a two-stage propensity match. Over a median of roughly three years, the composite outcome of IBD-related hospitalisation, steroid initiation, immunomodulation, new targeted therapy or major IBD surgery occurred at 11.9 per 100 person-years in the surgery group versus 15.1 in the non-surgery group, an adjusted hazard ratio of 0.66 (Stenberg 2025). That study was publicly funded, by the Swedish Research Council, Karolinska Institutet and regional bodies. Only 145 of the surgical patients had Crohn's disease, so the Crohn's-specific evidence within it is thin.
This is being taken seriously enough to generate a randomised trial. Eli Lilly is recruiting a phase 3 study of 290 adults with moderately to severely active Crohn's disease and overweight or obesity, comparing mirikizumab plus placebo against mirikizumab plus tirzepatide, with a primary endpoint that requires patients to simultaneously achieve CDAI clinical remission, endoscopic remission and at least 10% weight reduction (NCT06937099). Lilly manufactures both drugs, which is worth knowing when the results land. A trial being registered is not evidence of benefit, and until it reports, the honest answer is that nobody knows whether treating obesity improves Crohn's disease outcomes.
Meanwhile, the specialty is openly admitting the evidence is fragmented. A 2026 protocol paper describes an international initiative running three systematic reviews and a RAND/UCLA appropriateness consensus on obesity and cardiometabolic comorbidities in IBD, stating that these conditions influence disease activity, therapeutic response, surgical outcomes and quality of life "yet evidence remains fragmented" (Devi 2026). That is a protocol, not results. There are no recommendations in it yet.
The things obesity adds that Crohn's does not
Worth knowing because they are screenable, and because your IBD appointments probably are not covering them.
Fatty liver disease is common in this population. A systematic review and meta-analysis of 64 studies covering 1,532,811 individuals found a pooled prevalence of non-alcoholic fatty liver disease in IBD of 25.4%, higher in adults (26.0%) than children (7.0%) (Keetha Rao 2026). Two caveats on that paper's own numbers. Its pooled figure of 25.4% sits above both its named subtype estimates, 21.4% for ulcerative colitis and 22.8% for Crohn's disease, which we could not reconcile from the abstract. And its striking subgroup finding of 67% prevalence in Crohn's with upper gastrointestinal involvement carries a confidence interval of 1% to 99%, which is no information at all; the authors themselves caution that the subgroup findings rest on limited data.
Two negative findings in that literature are worth stating clearly because they cut against a common assumption. That meta-analysis found no significant association between fatty liver and any IBD medication it analysed, including corticosteroids (OR 1.43, 95% CI 0.89 to 2.32), anti-TNF agents, azathioprine, vedolizumab, ustekinumab and 5-ASA (Keetha Rao 2026). And a separate meta-analysis of 12 observational studies with 3,497 IBD participants found the pooled odds ratio for developing fatty liver in steroid users versus non-users was 0.87 (95% CI 0.72 to 1.04), with no significant heterogeneity, concluding steroids were not associated with fatty liver in IBD (Trivedi 2023). So if you have been told your fatty liver is the prednisolone's fault, the evidence does not support that.
The broader point, made by a 2026 review of cardiometabolic care in IBD, is that cardiovascular disease is a leading cause of death in IBD, that obesity prevalence in IBD has risen to around 40%, and that proactive cardiometabolic risk management is not prioritised in traditional IBD service models (Plush 2026). Blood pressure, lipids and glucose are not usually your gastroenterologist's job. They are worth asking your GP about rather than assuming someone is watching them.
Being disbelieved, and what the evidence says about it
The pattern people describe is consistent and the specific research is thinner than it should be. Both of those facts belong in the answer.
The threads are unambiguous. People describe going undiagnosed for years and attributing it to their weight, being told to lose weight rather than being investigated for visible rectal bleeding, being looked up and down and told they look healthy, and having a clinician read weight gain as proof a medication was working when it was not (r/CrohnsDisease thread). In a second thread, someone put the asymmetry precisely: doctors react to weight loss and have nothing to say about weight gain in someone who did not need to gain any (r/CrohnsDisease thread).
The general mechanism is documented. A review of empirical evidence across disciplines on obesity stigma in healthcare found that many providers hold strong negative attitudes and stereotypes about patients with obesity, that there is considerable evidence such attitudes influence person-perception, judgement, interpersonal behaviour and decision-making, and that experiences of or expectations of poor treatment can produce avoidance of care and mistrust (Phelan 2015). That review was about obesity care in general, not IBD, and it is a narrative review rather than a trial.
What we could not find, and looked for, is a study measuring diagnostic delay in Crohn's disease stratified by body weight. If it exists we did not locate it. So the honest statement is: the mechanism is well-documented in general healthcare, the pattern is consistently reported by patients with Crohn's, and nobody has measured the specific effect. That absence is not evidence it does not happen.
Practically, the counter to being read rather than heard is to arrive with numbers. Not adjectives about feeling awful, but stool counts, nights woken, calprotectin values with dates, and weight trends that make it visible that your weight has been flat while your symptoms moved. If you have been dismissed repeatedly, the escalation routes covered in how to get your doctor to take you seriously apply here too, even though that post is written around IBS.
Myths worth retiring
"You can't have Crohn's, you're not thin." Forty per cent of Crohn's outpatients in a matched case-control study had a BMI of 25 or above, statistically indistinguishable from their controls (Nic Suibhne 2013).
"Being heavier means your Crohn's is mild." Two studies support a version of that, two contradict it, and the six-year Swiss cohort found obese Crohn's patients had higher activity scores, lower remission rates and more complicated disease courses (Greuter 2020). No conclusion about your disease can be drawn from your BMI.
"Obesity makes biologics 60% more likely to fail." That figure comes from a meta-analysis whose authors state the effect was seen in rheumatic diseases and not in the IBD subgroup (Singh 2018). It is being quoted out of its own caveat.
"Your biologic is making you fat." A nationwide study of 851 patients starting infliximab found fewer than 3% gained more than 10% of their body weight, and concluded weight gain on anti-TNF therapy is unlikely to be a drug effect (Winter 2022). Smaller studies disagree (Kaazan 2020), so the point is that this is contested rather than established, not that nothing is happening to you.
"Your fatty liver is from the steroids." Two separate meta-analyses found no significant association between corticosteroid use and fatty liver in IBD (Trivedi 2023; Keetha Rao 2026).
"A normal BMI means your nutrition is fine." A normal BMI was falsely reassuring in 72% of IBD patients with low lean mass and 76% of those with sarcopenia (Bryant 2015).
"Losing weight will clear the creeping fat." Creeping fat is mesenteric tissue forming around inflamed bowel in response to translocated bacteria (Ha 2020). No study shows body weight loss removes it, and one study found visceral fat area did not even predict postoperative course (Argeny 2018).
"Being overweight caused your Crohn's." One pooled analysis of five prospective cohorts found a modest association with Crohn's incidence (Chan 2022); a meta-analysis of nine found none (Milajerdi 2022). Either way, population risk is not personal cause.
When to see a doctor promptly
Your weight has nothing to do with any of the following. See a doctor promptly if you have:
- New or increasing blood in your stool, or black tarry stools
- A fever alongside gut symptoms
- Unexplained weight loss, which still matters at any starting weight
- Severe or worsening abdominal pain
- Waking at night to open your bowels, when that is new for you
- A new or enlarging lump or swelling in your abdomen
- A new opening, swelling, pain or discharge near the anus
- Signs of anaemia such as breathlessness on mild exertion, dizziness or marked new fatigue
- Symptoms that are not settling despite your usual treatment
The honest bottom line
You can be overweight with Crohn's disease, you can be obese with Crohn's disease, and you can be either while having disease severe enough to need surgery. Around 40% of adult Crohn's patients are overweight or obese, which is roughly what you would find in a matched group without the condition.
Your weight is not a disease-activity readout. The studies that have asked disagree in both directions, and the only defensible individual conclusion is that nobody can grade your Crohn's from the outside. What weight does do is make one of your blood markers harder to read, since a higher BMI raises CRP independently of your bowel, and it hides low muscle mass and nutritional gaps that BMI was never designed to detect.
The reasons you might struggle to lose weight are mostly structural rather than personal: a safe-food list made of refined carbohydrate, steroid courses whose most common side effect is weight gain, activity constrained by fatigue and joints, and the oscillation of losing weight while ill and regaining it while well. None of that is solved by eating less during a flare, and none of it is a reason to touch your maintenance treatment.
What to do with all this is narrow and doable: track the signals that actually move with disease activity, know your own well-baseline CRP rather than reacting to single values, ask about drug levels rather than reasoning from your BMI, ask your GP who is watching your blood pressure, lipids and liver, and ask your IBD team for a dietitian if your safe-food list has shrunk. And if someone implies your disease cannot be serious because of how you look, the literature is on your side.
